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Abstract
The discovery of small molecules targeted to specific oncogenic pathways has revolutionized anti-cancer therapy. However,
such therapy often fails due to the evolution of acquired resistance. One long-standing question in clinical cancer research is
the identification of optimum therapeutic administration strategies so that the risk of resistance is minimized. In this paper,
we investigate optimal drug dosing schedules to prevent, or at least delay, the emergence of resistance. We design and
analyze a stochastic mathematical model describing the evolutionary dynamics of a tumor cell population during therapy.
We consider drug resistance emerging due to a single (epi)genetic alteration and calculate the probability of resistance
arising during specific dosing strategies. We then optimize treatment protocols such that the risk of resistance is minimal
while considering drug toxicity and side effects as constraints. Our methodology can be used to identify optimum drug
administration schedules to avoid resistance conferred by one (epi)genetic alteration for any cancer and treatment type.
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Introduction
Alteration of the normal regulation of cell-cycle progression,
division and death lies at the heart of the processes driving
tumorigenesis. A detailed molecular understanding of these
processes provides an opportunity to design targeted anti-cancer
agents. The term ‘targeted therapy’ refers to drugs with a focused
mechanism that specifically act on well-defined protein targets or
biological pathways that, when altered by therapy, impair the
abnormal proliferation of cancer cells. Examples of this type of
therapy include hormonal-based therapies in breast and prostate
cancer; small-molecule inhibitors of the EGFR pathway in lung,
breast, and colorectal cancers – such as erlotinib (Tarceva), gefitinib
(Iressa), and cetuximab (Erbitux); inhibitors of the JAK2, FLT3 and
BCR-ABL tyrosine kinases in leukemias – such as imatinib
(Gleevec), dasatinib (Sprycel), and nilotinib (Tasigna); blockers of
invasion and metastasis; anti-angiogenesis agents like bevacizumab
(Avastin); proapoptotic drugs; and proteasome inhibitors such as
bortezomib (Velcade) [1,2]. The target-driven approach to drug
development contrasts with the conventional, more empirical
approach used to develop cytotoxic chemotherapeutics, and the
successes of the past few years illustrate the power of this concept.
The absence of prolonged clinical responses in many cases,
however, stresses the importance of continued basic studies into
the mechanisms of targeted drugs and their failure in the clinic.
Acquired drug resistance is an important reason for the failure
of targeted therapies. Resistance emerges due to drug metabolism,
drug export, and alteration of the drug target by mutation,
deletion, or overexpression. Depending on the cancer type and its
stage, the therapy administered, and the genetic background of the
patient, one or several (epi)genetic alterations may be necessary to
confer drug resistance to cells. In this paper, we investigate drug
resistance emerging due to a single alteration. For example,
treatment of chronic myeloid leukemia (CML) with the targeted
agent imatinib fails due to acquired point mutations in the BCR-
ABL kinase domain [3]. To date, ninety different point mutations
have been identified, each of which is sufficient to confer resistance
to imatinib [4]. The second-generation BCR-ABL inhibitors,
dasatinib and nilotinib, can circumvent most mutations that confer
resistance to imatinib; the T315I mutation, however, causes
resistance to all BCR-ABL kinase inhibitors developed so far.
Similarly, the T790M point mutation in the epidermal growth
factor receptor (EGFR) confers resistance to the EGFR tyrosine
kinase inhibitors gefitinib and erlotinib [5], which are used to treat
non-small cell lung cancer. Other mechanisms of resistance
include gene amplification or overexpression of the P-glycoprotein
family of membrane transporters (e.g., MDR1, MRP, LRP) which
decreases intracellular drug accumulation, changes in cellular
proteins involved in detoxification or activation of the drug,
changes in molecules involved in DNA repair, activation of
oncogenes such as Her-2/Neu, c-Myc, and Ras as well as
inactivation of tumor suppressor genes like p53 [6–11].
The design of optimal drug administration schedules to
minimize the risk of resistance represents an important issue in
clinical cancer research. Currently, many targeted drugs are
administered continuously at sufficiently low doses so that no drug
holidays are necessary to limit the side effects. Alternatively, the
drug may be administered at higher doses in short pulses followed
PLoS Computational Biology | www.ploscompbiol.org 1 November 2009 | Volume 5 | Issue 11 | e1000557by rest periods to allow for recovery from toxicity. Clinical studies
evaluating the advantages of different approaches have been
ambivalent. Some investigations found that a low-dose continuous
strategy is more effective [12], while others have advocated more
concentrated dosages [13]. The effectiveness of a low-dose
continuous approach is often attributed to its targeted effect on
tumor endothelial cells and the prevention of angiogenesis rather
than low rates of resistance [14]. The continuous dosing strategy is
often implemented as combination therapy, sometimes including a
second drug administered at a higher dose in a pulsed fashion.
A significant amount of research effort has been devoted to
developing mathematical models of tumor growth and response to
chemotherapy. In a seminal paper, Norton and Simon proposed a
model of kinetic (not mutation-driven) resistance to cell-cycle
specific therapy in which tumor growth followed a Gompertzian
law [15]. The authors used a differential equation model in which
the rate of cell kill was proportional to the rate of growth for an
unperturbed tumor of a given size. They suggested that one way of
combating the slowing rate of tumor regression was to increase the
intensity of treatment as the tumor became smaller, thus
increasing the chance of cure. The authors also published a
review of clinical trials employing dosing schedules related to their
proposed dose-intensification strategy, and concluded that the
concept of intensification was clinically feasible, and possibly
efficacious [16]. Later, predictions of an extension of this model
were validated in a clinical trial evaluating the effects of a dose-
dense strategy and a conventional regimen for chemotherapy [17].
Their model and its predictions have become known as the
Norton-Simon hypothesis and have generated substantial interest
in mathematical modeling of chemotherapy and kinetic resistance.
For example, Dibrov and colleagues formulated a kinetic cell-cycle
model to describe cell synchronization by cycle phase-specific
blockers [18]; this model was then used for optimizing treatment
schedules to increase the degree of synchronization and thus the
effectiveness of a cycle-specific drug. Agur introduced another
model describing cell-cycle dynamics of tumor and host cells to
investigate the effect of drug scheduling on responsiveness to
chemotherapy [19]; this model was then used to optimize
scheduling of chemotherapeutics to maximize efficacy while
controlling host toxicity. Other theoretical studies include a
mathematical model of tumor recurrence and metastasis during
periodically pulsed chemotherapy [20], a control theoretic
approach to optimal dosing strategies [21], and an evaluation of
chemotherapeutic strategies in light of their anti-angiogenic effects
[14]. For a more comprehensive survey of kinetic models of tumor
response to chemotherapy, we refer the reader to reviews [22–24]
and references therein.
There have also been substantial research efforts devoted to
developing mathematical models of geneticresistance, i.e. resistance
driven by genetic alterations in cancer cells. Since mutations
conferring resistance can arise as random events during the DNA
replication phase of cell division, the dynamics of resistant
populations are well-suited to description with stochastic mathe-
matical models. Coldman and co-authors pioneered this field by
introducing stochastic models of resistance against chemotherapy to
guide treatment schedules (see e.g., [25,26] and references therein).
In 1986, Coldman and Goldie studied the emergence of resistance
to one or two functionally equivalent chemotherapeutic drugs using
a branching process model of tumor growth with a differentiation
hierarchy [25]. In this model, the birth and death rates of cells were
time-independent constants and each sensitive cell division gave rise
to a resistant cell with a certain probability. The effect of drug was
modeled as an additional probabilistic cell kill law on the existing
population, and the drug could be administered in a fixed dose at a
series of fixed time points.The goal of the model wasto schedule the
sequential administration of both drugs in order to maximize the
probability of cure. Later, the assumption of equivalence or
‘symmetry’ between the two drugs was relaxed [27]. These models
were also extended to include the toxic effects of chemotherapy on
normal tissue, and an optimal control problem was formulated to
maximize the probability of tumor cure without toxicity [26]. More
recently, Iwasa and colleagues used a multi-type birth-death process
model to study the probability of resistance emerging due to one or
multiple mutations in populations under selection pressure [28].
The authors considered pre-existing resistance mutations and
determined the optimum intervention strategy utilizing multiple
drugs. Multi-drug resistance was also investigated using a multi-type
birth-death process model in work by Komarova and Wodarz
[29,30]. In their models, the resistance to each drug was conferred
by genetic alterations within a mutational network. The birth and
death rates of each cell type were time-independent constants and
cellshad anadditionaldrug-induceddeathrateif theyweresensitive
to one or more of the drugs. The authors studied the evolution of
resistant cells both before and after the start of treatment, and
calculated the probability of treatment success under continuous
treatment scenarios with a variable number of drugs. Recently, the
dynamics of resistance emerging due to one or two genetic
alterations in a clonally expanding population of sensitive cells
prior to the start of therapy were studied using a time-homogenous
multi-type birth-death process [31,32].
One common feature of these models of genetic resistance is
that the treatment effect is formulated as an additional
probabilistic cell death rate on sensitive cells, separate from the
underlying birth and death process model with constant birth and
death rates. Under these model assumptions, the drug cannot alter
the proliferation rate of either sensitive or resistant cells; however,
a main effect of many targeted therapies (e.g. imatinib, erlotinib,
gefinitib) is the inhibition of proliferation of cancer cells. Inhibited
proliferation in turn leads to a reduced probability of resistance
since resistant cells are generated during sensitive cell divisions. In
this paper, we utilize a non-homogenous multi-type birth-death
process model wherein the birth and death rates of both sensitive
Author Summary
Recently, the field of anti-cancer therapy has witnessed a
revolution by the discovery of targeted therapy, which
refers to compounds targeting specific pathways causing
abnormal growth of cancer cells. The clinical success of
such drugs has been limited by the evolution of acquired
resistance to these compounds, which leads to a relapse
after initial response to therapy. Current dosing proce-
dures are not designed to optimally delay the emergence
of resistance; the identification of such optimal dosing
schedules represents an important challenge in clinical
cancer research. Here, we design a novel methodology to
identify the optimum drug administration strategies that
reach this clinical goal. Our model describes the evolu-
tionary dynamics of a tumor cell population during
therapy. We consider drug resistance emerging due to a
single (epi)genetic alteration and calculate the probability
of resistance arising during specific dosing strategies. We
then optimize treatment protocols such that the risk of
resistance is minimal while considering drug toxicity and
side effects as constraints. Since this methodology can be
extended to describe situations arising during administra-
tion of cytotoxic chemotherapy as well, it can be used to
identify optimum drug administration schedules to avoid
resistance for any cancer and treatment type.
Evolution of Resistance to Targeted Therapies
PLoS Computational Biology | www.ploscompbiol.org 2 November 2009 | Volume 5 | Issue 11 | e1000557and resistant cells are dependent on a temporally varying drug
concentration profile. This study represents a significant departure
from existing models of resistance since we incorporate the effect
of inhibition of sensitive cell proliferation as well as drug-induced
death, obtaining a more accurate description of the evolutionary
dynamics of the system. In addition, we generalize our model to
incorporate partial resistance, so that the drug may also have an
effect on the birth and death rates of resistant cells. The goals of
our analysis also differ from those of previous work. Coldman and
Murray were interested in finding the optimal administration
strategy for multiple chemotherapeutic drugs in combination or
sequential administration [26]; they aimed to maximize the
probability of cure while limiting toxicity. Komarova was
interested in studying the effect of multiple drugs administered
continuously on the probability of eventual cure [30]. In contrast,
in this paper we derive estimates for the expected size of the
resistant cell population as well as the probability of resistance
during a full spectrum of continuous and pulsed treatment
schedules with one targeted drug. We then propose a methodology
for selecting the optimal strategy from this spectrum to minimize
the probability of resistance as well as to maximally delay the
progression of disease by controlling the expected size of the
resistant population, while incorporating toxicity constraints. In
many clinical scenarios, the probability of resistance is high
regardless of dosing strategy, and thus the maximal delay of
disease progression is a more realistic objective than tumor cure.
The methodology developed in this paper can be applied to study
acquired resistance in any cancer and treatment type.
Methods
Consider a population of M drug-sensitive cancer cells at the
time of diagnosis. These cells may represent the total bulk of tumor
cells or, alternatively, cancer stem cells only; if only the latter cells
are capable of self-renewal to produce and maintain a resistant cell
clone, then the effective population size M equals the number of
cancer stem cells in the tumor. We assume for now that there are
no resistant cells present at the time of diagnosis; this assumption
will be relaxed in later sections. The evolutionary dynamics of the
sensitive and resistant cancer cell populations are modeled as a
multi-type branching process [33].
Let us first consider this process during a continuous dosing
schedule. Cells are chosen at random to divide or die in
accordance with a specified growth and death rate. During
therapy, the growth and death rates of sensitive cancer cells are
denoted by q1 and c1, respectively. During each sensitive cancer
cell division, a resistant cell arises with probability u; such a cell has
growth and death rates q2 and c2 during treatment. The growth
and death rates during therapy are determined by the dose
intensity of treatment.
Let Xt denote the random process representing the number of
sensitive cancer cells at time t, and let Yt denote the number of
resistant cancer cells at time t. The initial conditions at the start of
treatment, t~0, are defined as X0~M and Y0~0. Denote the
state of the process after the n-th event (represented by a cell birth
or death) as (Xn,Yn). The transition probabilities of the stochastic
process are given by
P((Xnz1,Ynz1)~(Xnz1,Yn)jXn,Yn)~q1Xn(1{u)=Rn,
P((Xnz1,Ynz1)~(Xn{1,Yn)jXn,Yn)~c1Xn=Rn,
P((Xnz1,Ynz1)~(Xn,Ynz1)jXn,Yn)~(q2Ynzq1Xnu)=Rn,
P((Xnz1,Ynz1)~(Xn,Yn{1)jXn,Yn)~c2Yn=Rn:
Here Rn~Xn(q1zc1)zYn(q2zc2) is the sum of the rates,
normalizing the total probability to 1. The arrival times between
events are exponentially distributed: if tn denotes the time at the
beginning of the n-th step, then tnz1{tn is an exponential
random variable with parameter Rn.
Let us now consider the evolution of these cell populations
during general pulsed treatment schedules. To investigate dosing
strategies consisting of drug pulses and treatment holidays, we
implement time-varying growth and death rates in the stochastic
process model. During treatment pulses, the growth rates of
sensitive and resistant cells are again denoted by q1 and q2,
respectively, while their death rates are given by c1 and c2. During
drug holidays, the growth rates of sensitive and resistant cells are
given by r1 and r2, respectively, and their death rates by d1 and d2
(see Table 1 for a summary of notation). Here we assume that the
drug reaches its maximum concentration immediately after
Table 1. Notation.
Symbol Definition (units, where applicable)
Xt Number of sensitive cancer cells at time t
Yt Number of resistant cancer cells at time t
M Initial number of sensitive cancer cells
q1 Growth rate of sensitive cancer cells during therapy (time
21)
c1 Death rate of sensitive cancer cells during therapy (time
21)
q2 Growth rate of resistant cancer cells during therapy (time
21)
c2 Death rate of resistant cancer cells during therapy (time
21)
r1 Growth rate of sensitive cancer cells during treatment break (time
21)
d1 Death rate of sensitive cancer cells during treatment break (time
21)
r2 Growth rate of resistant cancer cells during treatment break (time
21)
dt Death rate of resistant cancer cells during treatment break (time
21)
Ton Length of treatment pulse (time)
Toff Length of treatment break (time)
u Mutation rate per sensitive cell division
pi,0 Number of sensitive cancer cells at beginning of i-th treatment cycle
pi,1 Number of sensitive cancer cells at end of i-th treatment cycle
B Number of sensitive cell divisions before extinction of sensitive cell
population
W Number of treatment cycles before extinction of sensitive cell
population
Wt Number of treatment cycles until time t
P Probability of resistance
R(T) Expected number of resistant cells at time T
T
i
j Example toxicity constraint (i-th member of j-th family)
KT on + Toff
aon q12c1
aoff r12d1
c aonTon + aoffToff
This table shows frequently used notation.
doi:10.1371/journal.pcbi.1000557.t001
Evolution of Resistance to Targeted Therapies
PLoS Computational Biology | www.ploscompbiol.org 3 November 2009 | Volume 5 | Issue 11 | e1000557administration and remains at that level until the beginning of the
treatment break; additionally, we assume that the intensity of the
dose does not vary from pulse to pulse. The length of each
treatment pulse is denoted as Ton and the length of each treatment
break is denoted as Toff. Each treatment cycle consists of one pulse
and one break, and every treatment cycle has the same length:
K~TonzToff. Thus, a strategy in which Toff~0 corresponds to
the continuous dosing regimen. Both sensitive and resistant cells
expand in the absence of therapy, r1wd1 and r2wd2. We consider
only drugs at concentrations that lead to a reduction of the
sensitive cancer cell population (q2vc2). The (epi)genetic
alteration conferring resistance may be neutral (r1~r2), advanta-
geous (r1vr2), or disadvantageous (r1wr2) in the absence of
therapy. If r2~q2 and d2~c2, then the drug has no effect on
resistant cancer cells and the mutation confers complete resistance;
it is this case that we consider first. We investigate only viable
treatment options (i.e. dosing strategies that are capable of
depleting the sensitive cancer cell population). Specifically, we
define aon:q1{c1, aoff:r1{d1, and c:aonTonzaoffToff, and
require that the relation cv0 must hold. This criterion ensures
that the sensitive cell population decreases on average over time. If
this criterion is not met, the question of resistance becomes less
important as the treatment schedule does not prevent the
expansion of the sensitive cancer cell population. Figure 1 shows
an example of the dynamics of sensitive cancer cells during
continuous and pulsed drug administration.
The probability of resistance
Let us now calculate the probability of resistance during a given
dosing schedule. Under the assumption of complete resistance, the
probability of extinction of a resistant cell clone starting from one
resistant cell is d2=r2, regardless of which dosing strategy is used
[33]. The number of resistant cells produced from the sensitive cell
population is on average proportional to the number of sensitive
cell divisions; these two quantities are related through the
mutation rate u.
As a preliminary calculation, consider the behavior of the
sensitive cell population, Xt, with constant growth rate q1 and
death rate c1. Under the assumption that the mutation rate u is
small enough such that the stochastic emergence of resistant cells
from sensitive cells has negligible effects on the sensitive cell
number, we approximate Xt as a simple birth-death process.
Recall that the initial size of the sensitive cell population is M; then
the mean abundance of the sensitive cell population at time t is
approximated as p(t)~ ½Xt ~M exp½aont . The number of
sensitive cell divisions in the time interval ½0,T  is approximately
given by
b(T,q1,c1,M)~
ðT
0
Mq1 exp½(q1{c1)s ds
~
Mq1
q1{c1
(exp½(q1{c1)T {1):
ð1Þ
The number of surviving resistant cell clones arising from the
sensitive cell population in the time interval ½0,T  is then
binomially distributed as Bin(b(T,q1,c1,M),u(1{d2=r2)).
Let us now study the probability of resistance under a general
pulsed treatment regimen. Define pi,0 as the expected number of
sensitive cancer cells at the beginning of the ith treatment cycle,
and pi,1 as the expected number of sensitive cancer cells at the
beginning of the ith treatment holiday. Then we have
p1,1~MeaonTon, p2,0~p1,1eaoff Toff, p2,1~p2,0eaonTon, etc. We obtain
the general formulae for the number of sensitive cancer cells at the
beginning and end of the ith treatment cycle as
pi,0~Me(i{1)c ð2Þ
pi,1~Me(i{1)ceaonTon,
where c~aonTonzaoffToff. The number of cycles W before
extinction of the sensitive cell population is approximated as
W&ceil½ln(1=M)c{1 . To estimate the total number of sensitive
cancer cell births before extinction, we sum the number of births
during the on- and off-treatment phases over all cycles. Let Ci be
the number of sensitive cancer cell births during the ith on-
treatment phase and Di the number of births during the ith off-
treatment phase. The expected number of births, B, during the
entire treatment regime is then approximated as
B:
X W
i~1
CizDi~
X W
i~1
b(Ton,q1,c1,pi,0)zb(Toff,r1,d1,pi,1): ð3Þ
Here b is the estimated number of sensitive cancer cell divisions in
the treatment interval, evaluated as in equation (1). Next, let us
define the functions f(T,q1,c1)~
q1
q1{c1
eT(q1{c1){1
  
and
F~½1{eWc =½1{ec . We can express each sum as the geometric
series
X W
i~1
Ci~Mf(Ton,q1,c1)
X W
i~1
ec(i{1)~Mf(Ton,q1,c1)F, ð4Þ
X W
i~1
Di~Mf(Toff,r1,d1)eaonTonF:
Then we obtain the expected number of sensitive cancer
cell births during the entire duration of therapy as
B~FM f(Ton,q1,c1)zf(Toff,r1,d1)eaonTon   
. We can approximate
F with F&(1{1=M)=(1{ec). Substituting in the correct
expressions for f(Ton,q1,c1) and f(Toff,r1,d1), we obtain a final
estimate for the number of sensitive cell divisions before the
extinction of sensitive cells as
B&
M{1
1{ec
  
q1
q1{c1
eaonTon{1
  
z
r1
r1{d1
eaoff Toff {1
  
eaonTon
  
:
The number of surviving resistant cell clones produced from the
sensitive cell population is a random variable with distribution
Bin(B,u(1{d2=r2)). We can thus make a Poisson approximation
to estimate the probability that at least one surviving resistant cell
clone is produced before the extinction of sensitive cells as
P~1{e{Bu(1{d2=r2): ð5Þ
In the special case of continuous dosing, Toff~0, the number of
sensitive cell divisions is approximated by
Evolution of Resistance to Targeted Therapies
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(1{M)q1
q1{c1
: ð6Þ
As a consistency check, this formula can also be arrived at via
equation (1) with the initial size of the sensitive cancer cell
population, M, and the amount of time until the extinction of the
sensitive cells, T&log(1=M)=aon. Then the probability of
resistance emerging during continuous dosing is again calculated
using formula (5) with equation (6).
When the (epi)genetic alteration confers partial resistance to the
cell (i.e. when r2=q2 and/or c2=d2), then the probability of
resistance emerging during continuous dosing is given by
P~1{e{Bu(1{c2=q2), ð7Þ
where B is again calculated as in equation (6). To accommodate
this modification in pulsed schedules, we introduce ‘effective’
growth and death rates for resistant cells. The effective growth rate
of resistant cells is given by qeff,2~½q2Tonzr2Toff =½TonzToff ,
Figure 1. The dynamics of sensitive cancer cells during continuous and pulsed anti-cancer therapy. Subfigure (A) shows the dosing
schedule specified by the growth rate of sensitive cancer cells as a function of time. The dashed line represents a dosing schedule in which the drug is
administered at the maximum dose tolerated without treatment breaks. The solid line represents a schedule in which the drug is administered in
pulses followed by drug holidays. Subfigures (B) and (C) show sample paths for the sensitive cell population during pulsed and continuous therapy,
respectively. During treatment pulses as well as during continuous therapy, the sensitive cancer cell population declines while it expands during
treatment breaks. Parameters are M=10000, r1=1.75, d1=1.0, c1=1.0, Ton=3.0, and Toff=1.0.
doi:10.1371/journal.pcbi.1000557.g001
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½c2Tonzd2Toff =½TonzToff . For general pulsed schedules, the
probability of resistance is then approximated by
P~1{e{Bu(1{ceff,2=qeff,2), ð8Þ
where B is calculated as in equation (5).
The expected number of resistant cells
We next approximate the expected number of resistant cancer
cells at time t. To calculate this quantity, we estimate the number
of surviving resistant cell clones produced during each small time
interval and then calculate the growth of each resistant cell clone
until time t. More precisely, we take the convolution of the rate of
production of resistant cell clones from the sensitive cell process
with the average rate of clonal expansion of resistant cells.
Let us first consider general pulsed treatment schedules. Using
methods from the previous section, we find that the expected
number of sensitive cancer cell divisions until time t is given by
B(t)~
1{eWtc
1{ec
  
M(f(Ton,q1,c1)zf(Toff,r1,d1)eaonTon):
Here Wt denotes the fractional number of treatment cycles until
time t. After making the approximation Wt&t=(TonzToff),w e
have
B’(t)&
cect=½TonzToff  
(ec{1)(TonzToff)
M(f(Ton,q1,c1)zf(Toff,r1,d1)eaonTon): ð9Þ
Since the number of resistant cells produced directly from the
sensitive cell population until time t is binomially distributed,
Bin(B(t),u), the expected number of such cells is given by B(t)u.
Thus we estimate the average number of resistant cells at time T
as
R(T)~u
ðT
0
B’(t)exp½(T{t)(r2{d2) dt ð10Þ
&
Muc
ec{1
{eT(r2{d2)zeTc=½TonzToff  
(d2{r2)(ToffzTon)zc
q1
aon
eTonaon{1
  
z
r1
aoff
eToff aoff {1
  
eaonTon
  
:
In the special case of continuous dosing strategies, Toff~0, the
average number of resistant cells at time T is given by
R(T)~Muq1
e(q1{c1)T{e(r2{d2)T
(q1{c1){(r2{d2)
: ð11Þ
Once again we can check for consistency by deriving this formula
via equation (1). Recall that the expected number of sensitive
cancer cell births starting from a population of size M until time T
is given by b(T,q1,c1,M) (equation (1)). Then the expected
number of resistant cells produced is b(T,q1,c1,M)u, and the
expected number of resistant cells at time T is given by
R(T)~u
ðT
0
Lb
Lt
exp½(r2{d2)(T{t) dt
~Mu
ðT
0
q1exp½t(q1{c1) exp½(r2{d2)(T{t) dt
~Muq1
e(q1{c1)T{e(r2{d2)T
(q1{c1){(r2{d2)
:
We are also interested in calculating the expected number of
resistant cells averaged only over those patients who develop
resistance. This quantity is clinically relevant since many treatment
choices may inevitably lead to resistance; in those cases, the drug
should be dosed in such a way that the number of resistant cells is
minimum, thereby maximizing the time until detection of
resistance and disease progression. Mathematically, this amounts
to estimating the expected size of the resistant cell population,
conditioned on the event that at least one surviving resistant clone
is produced prior to the extinction of sensitive cancer cells. We
make the approximation that the expected resistant cell number,
conditioned on the complementary event of no surviving resistant
cell clones, is negligible. Then the expected number of resistant
cells averaged over the cohort of patients who develop resistance is
estimated as
S(T)~
R(T)
P
: ð12Þ
Pre-existing resistance
Suppose that at the start of therapy there exists a small
population of resistant cells. We may then adapt the theory to
calculate the probability of resistance and expected size of the
resistant clone under various dosing schedules. Let us consider the
initial population as two separate populations: M(1{s) sensitive
cells and Ms resistant cells, where s is the initial fraction of
resistant cells (assume for simplicity that Ms is an integer). Then
the probability of avoiding resistance is given by the probability
that the pre-existing resistant cell clones become extinct times the
probability that the initial sensitive cell population does not give
rise to any surviving resistant clones during treatment. Let Ps
denote the probability, calculated as in equation (5), of de novo
resistance arising from the initial sensitive population of size
M(1{s). The probability of extinction of the pre-existing clone is
given by Pe
r~1{(q2=c2)
Ms if q2vc2 and Pe
r~1 otherwise. (Note
that q2 and c2 may be replaced by qeff,2 and ceff,2 in the case of
pulsed schedules with partial resistance). Then the total probability
of resistance is given by
P~1{(1{Ps)Pe
r: ð13Þ
Let Rs(T) represent the expected number of resistant cells arising
from the initial sensitive cell population of size M(1{s),
calculated as in equation (10). The expected number of resistant
cells at time T is given by Rs(T) plus the expected current size of
the initially resistant population. Thus we have
R(T):Rs(T)zMsexp½(q2{c2)T , ð14Þ
where once again the rates q2 and r2 may be replaced by their
effective values in the case of pulsed therapy with partial
resistance.
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Exact stochastic simulations of the process (Xt,Yt) are
performed using the standard Monte Carlo technique; each time
an event occurs, a cell is chosen to divide or die based on the
current cell growth and death rates and the population size of each
cell type. When the drug concentration changes, the cell growth
and death rates are modified accordingly.
Let us now investigate the fit between the analytic approxima-
tions and exact stochastic computer simulations, as well as the
parameter dependence of these approximations. We first study the
dependence of the probability of resistance emerging during a
continuous dosing schedule on the growth rate of sensitive cancer
cells during therapy, q1 (Fig. 2A), and their initial number, M
(Fig. 2B). The simulations exhibit a good fit with the analytical
approximations. As the growth rate of sensitive cells during
therapy (q1) increases, the risk of developing resistance increases as
well. Similarly, as the initial size of the sensitive cancer cell
population increases, the number of sensitive cell divisions until
extinction becomes larger, thus enhancing the likelihood of
producing a successful resistant cell clone. Hence the probability
of developing resistance also increases with M.
We next investigate the expected number of resistant cells as a
function of time for varying growth rates of sensitive and resistant
cells during continuous treatment. When the sensitive cell growth
rate during treatment, q1, increases and the growth rate of
resistant cells, q2, is kept constant, then the expected number of
resistant cells increases (Fig. 2C). This behavior is apparent from
Figure 2. The probability of resistance and expected number of resistant cells during continuous therapy. (A) The probability of
developing resistance during continuous therapy as a function of the growth rate of sensitive cells during treatment, q1. The probability of resistance
increases with the growth rate. Solid lines represent the analytical approximations and Monte Carlo simulation results are plotted as dots. Parameters
are M=10000, q2=1.25, u=10
25, and c1=c2=1.0. (B) We show the probability of developing resistance during continuous therapy as a function of
the number of sensitive cancer cells at diagnosis, M. The probability of resistance increases linearly with M. Parameters are q1=0.75 and all others as
in (A). (C) We show the expected number of resistant cells as a function of time during continuous therapy for different values of the growth rate of
sensitive cells during treatment, q1. The expected number of resistant cells increases with time and with q1. Parameters are M=1000, q2=1.2,
u=10
24, and c1=c 2=1.0. (D) We show the expected number of resistant cells as a function of time during continuous therapy for different values of
the growth rate of resistant cells during treatment, q2. The expected number of resistant cells increases with time and with q2. Parameters are q1=0.5
and all others as in (C).
doi:10.1371/journal.pcbi.1000557.g002
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is always negative, thus making exp½(q2{c2)T  the dominant term
in the numerator. Therefore the growth rate of the expected
population size is dominated by the growth rate of resistant cells at
later times as the other time-dependent term in the numerator
approaches zero. Figure 2D confirms that as q2 increases, the
expected number of the resistant cell population also increases.
Let us now consider treatment schedules incorporating pulsed
doses and treatment holidays. We first investigate the dependence
of the probability of resistance on the growth rates of sensitive and
resistant cancer cells during treatment phases, q1 and q2, the
duration of each treatment pulse, Ton, and the initial number of
sensitive cancer cells, M (Figs. 3A–D). As in the case of continuous
dosing, the probability of resistance increases as q1 and q2
increase. An increase in the duration of each treatment pulse, Ton,
decreases the probability of resistance while an increase in M
linearly enhances the risk of resistance. The parameter depen-
dence of the expected number of resistant cells as a function of
time is shown in Figs. 3E and 3F. The expected number of
resistant cells increases with increasing growth rates of sensitive
and resistant cancer cells during therapy (q1 and q2).
Optimizing dosing strategies
Using the estimates derived above, we now propose a method
for optimizing dosing strategies to minimize the probability of
resistance. In cases where the emergence of resistance is certain,
this method will predict a dosing strategy that maximally delays
the detection of resistance by minimizing the number of resistant
cancer cells. The optimal dosing strategy is selected from a range
of tolerated treatment schedules specified by toxicity constraints.
In practice, these toxicity constraints, in addition to the growth
and death rates of sensitive and resistant cells at varying dose
levels, must be determined experimentally for each drug and
cancer type. In the following we will construct example toxicity
constraints to demonstrate the methodology and test for sensitivity
to the constraint profile.
A modification of treatment schedules can change the duration
of each treatment pulse (affecting Ton and Toff), the intensity of the
dose (affecting growth and death rates of sensitive cancer cells, q1
and c1), or both. When considering complete resistance, the
growth and death rates of resistant cells are unaltered by changing
treatment strategies. We assume that all other parameters are
unaffected by changes in administration schedules as well. Thus,
we consider toxicity constraints to provide a bounded domain in
the four-dimensional parameter space spanning Ton,Toff,q1, and
c1. We can immediately reduce the dimension of the constraint
domain to two, since Ton specifies Toff explicitly through the fixed
length of the treatment-and-break cycle, K~TonzToff, and q1
and c1 are both dependent on the concentration of the drug and
thus cannot vary independently. Therefore, we consider toxicity
constraints in the form of a function specifying the maximum
amount of time, Ton, that a drug can be administered to a patient
at a particular concentration before causing dose-limiting
toxicities. In the following, we make the simplifying assumption
that this drug concentration specifies the death rate of sensitive
cancer cells, c1, and does not alter the growth rate, q1;
alternatively, we can also investigate treatment strategies that
modulate the growth rate rather than the death rate of sensitive
cancer cells, or both. We assume that such relationships between
Ton and c1 are monotonically decreasing functions of c1; see
Figure 4A for an example of a toxicity constraint.
From clinical trial data we obtain the maximum amount of time
for which a range of drug concentrations are tolerated, leading to a
relationship between Ton and the drug concentration. The effect of
particular drug concentrations on c1 and/or q1 may then be found
experimentally by exposing sensitive cancer cells to drug doses and
measuring the growth and death rates in vitro. Such investigations
identify a toxicity constraint relating Ton and c1. We display
example constraint functions in Figures 4B and 4C.
We next show some example toxicity data for the targeted drug
erlotinib, which is an EGFR inhibitor used in treating solid
malignancies such as non-small cell lung cancer. Compiling data
from several clinical trials [34–36], we obtain a relationship
between the drug dose and plasma concentration (measured as the
maximum concentration achieved after a single dose). This data is
plotted in Figure 5A; here we observe a relatively linear
relationship between dose and plasma concentration. We also
compiled data points on the number of days each particular dose
was tolerated in continuous daily administration. We converted
each dose level to concentration using the linear relationship
found, and plot these points in Figure 5B. A conservative toxicity
constraint in terms of Ton vs. concentration is plotted, where we
assume that any concentration or length of pulse increased beyond
what was tolerated in the trials would not be admissible. This
toxicity constraint, in conjunction with further experimental data
on the growth and death rates of sensitive and resistant cancer cells
at various concentrations, would enable us to calculate optimal
dosing schedules for this specific system using our model.
For our theoretical investigations, we now introduce several
example families of toxicity constraints to test for sensitivity of the
probability of resistance to several key aspects of the shape of the
curve. All of these example constraints are convex, monotonically
decreasing functions of c1. Thus we have implicitly assumed that
as the drug concentration increases and the cell death rate
increases, the maximum tolerated length of a treatment pulse
decreases. In the first family, we vary the maximum dose that can
be tolerated for the full treatment schedule of K days. In the
second family we vary the maximum dose that can be tolerated for
just one day, and in the third family we vary the degree of
convexity of the constraint curve, or the initial rate of decrease in
Ton as the concentration increases.
Consider the first family of toxicity curves in Figure 6A,
specified by
Ti
1(c1)~
AiK
(c1{Bi)
2 , for i~1,2,3, ð15Þ
where Bi~(K1=2ai{6)=(K1=2{1) for a1~2:1, a2~2:3, a3~2:5
and Ai~(6{Bi)
2=K. In our notation, Ti
j, the subscript j denotes
the constraint family and the superscript i indicates a specific
function belonging to this family. These constraints serve to vary
the endpoint representing the maximum dose that can be tolerated
for a full treatment cycle (K days) while fixing the endpoint
representing the maximum dose that is tolerated for just one day of
a treatment cycle, specified by the death rate c1~6. In other
words, in this family of constraints we vary the continuous-dose
concentration endpoint (represented by black circles in Figure 6A)
of the toxicity constraint via the parameter ai, while keeping the
form of the constraint and the high-dose concentration endpoint
fixed.
We also test for sensitivity to two other aspects of the toxicity
constraints: the high-dose concentration endpoint (i.e. the
maximum dose that is tolerated for just one day) and the degree
of concavity of the curve. Figure 6B shows a family of constraints
varying the high-dose endpoints (shown in black circles). These
example constraints are specified by equation
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PLoS Computational Biology | www.ploscompbiol.org 8 November 2009 | Volume 5 | Issue 11 | e1000557Figure 3. The probability of resistance and expected number of resistant cells during pulsed therapy. (A) We show the probability of
resistance during pulsed therapy as a function of the growth rate of sensitive cancer cells during each treatment phase, q1. The risk of resistance
increases as the growth rate is enhanced. Lines represent the analytical predictions and dots show the Monte Carlo simulation results. Parameters are
M=1000, r1=1.3, r2=q2=1.1, u=10
24, and d1=d2=c1=c2=1.0. (B) We show the probability of resistance during pulsed therapy as a function of the
growth rate of resistant cancer cells during a treatment phase, q2. The risk of resistance increases as the growth rate is enhanced. Parameters are
q1=0.5 and all others as in (A). (C) We show the probability of resistance during pulsed therapy as a function of the duration of each treatment phase,
Ton. The risk of resistance decreases as the pulse becomes longer. Parameters are as above. (D) We show the probability of resistance during pulsed
therapy as a function of the initial size of the sensitive cancer cell population, M. The risk of resistance increases with M. Parameters are as above. (E)
and (F) We show the expected number of resistant cells as a function of time during pulsed therapy when q1, (E), and q2, (F), are varied. The expected
number of resistant cells increases with both quantities. Parameters are as above.
doi:10.1371/journal.pcbi.1000557.g003
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2(c1)~
AiK
(c1{Bi)
2 , for i~1,2,3, ð16Þ
where Bi~(2:3K1=2{bi)=(K1=2{1) for b1~5,b2~6,b3~7 and
Ai~(bi{Bi)
2=K. Likewise, a family of constraints varying the
degree of convexity is exhibited in Figure 6C and specified by the
following equations:
T1
3(c1)~Aic1zBi, ð17Þ
T2
3(c1)~
Ai
c1
zBi,
T3
3(c1)~
Ai
(c1{Bi)
2 ,
where, for each function, the Ai and Bi are determined by setting
the endpoints to be
Ti
3(6)~1, ð18Þ
Ti
3(2:3)~K:
Once the toxicity constraint is established (e.g. Figure 4), the
tolerable range of treatment schedules is specified by the area
under the curve on the (Ton,c1){plane. We then aim to locate the
optimal point within this area that minimizes the probability of
resistance. In situations in which the optimum probability of
resistance is 1 or close to 1, we aim to locate the optimal point
minimizing the expected number of resistant cells conditional on
developing resistance, thus maximizing the time until disease
progression. We note from the analytical approximations that a
change in the mutation rate u does not modify the choice of
optimal dosing schedule. We also observe from our analytical
approximations that the optimizing points must always lie directly
on the toxicity constraint curve itself – intuitively, any point lying
below the toxicity curve represents a weaker than tolerated dosing
schedule and hence cannot minimize the risk of resistance. Once a
minimizing point is located, the optimal treatment schedule is
entirely specified since the duration of treatment pulses are given
by Ton, the length of the drug holiday is given as the remainder of
the cycle duration (Toff~K{Ton), and the intensity of the dose is
specified by the death rate of sensitive cells, c1.
To illustrate this concept, let us consider the toxicity constraint
T1
1 from equation (15). Recall the constraint cv0 restricting the
treatment schedules to viable dosing strategies in which the
population of sensitive cells decreases overall in time. This
constraint may restrict the domain of the toxicity curve to a
limited range of c1. For the current example, this restriction is
shown in Figure 5. We can then calculate the probability of
resistance, the expected number of resistant cells, and the
conditional expected number of resistant cells over the range of
treatment schedules specified by this restricted constraint curve.
Note again that in the formula describing the expected number of
resistant cells, equation (10), the growth rate of R(T) is dominated
by the growth rate of resistant cells, exp½(d2{r2)T , at later times,
since the other time-dependent term in the expression,
Figure 4. Examples for toxicity constraints. Subfigure (A) shows
an example toxicity constraint in the form of a function defining the
maximum tolerated duration of treatment, Ton, versus the death rate of
sensitive cancer cells during therapy, c1, for a 28-day treatment cycle.
This type of toxicity constraint can be derived from experimental and
clinical data in the form shown in subfigures (B) and (C). In subfigure (B),
we display an example of the type of data available from clinical trials
that relate Ton to the drug concentration. Hence for a given drug
concentration, a treatment pulse of Ton days was tolerated. In (C), we
show an example of how the drug concentration can be related to the
death rate of sensitive cancer cells during treatment, c1, through in vitro
experiments.
doi:10.1371/journal.pcbi.1000557.g004
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PLoS Computational Biology | www.ploscompbiol.org 10 November 2009 | Volume 5 | Issue 11 | e1000557Figure 5. Erlotinib pharmacokinetic data and toxicity constraint. Subfigure (A) shows the relationship between dose and plasma Cmax
concentration obtained after a single dose (mM). These data were reported in [34,36]. Subfigure (B) shows points depicting clinically tolerated
schedules, as reported in [34–36]. The doses administered are converted to plasma concentration using the linear relationship found in subfigure (A).
We also plot a conservative toxicity constraint where we assume that any concentration or length of pulse increased to levels beyond those tolerated
in the trials would not be admissible.
doi:10.1371/journal.pcbi.1000557.g005
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can neglect the latter term when considering the long-term growth
of the resistant cell population. Rewrite equation (10) as
R(T)&CRe(d2{r2)T. Here CR is the time-independent constant
comprised of the remaining terms in equation (10) except for
exp½Tc=(TonzToff) . Analogously, the expected number of
resistant cells conditional to the emergence of resistance is
approximated by A(T)&CRe(d2{r2)T=P.
In Figures 7A–C, we show the probability of resistance, P, the
time-independent term of the equation describing the number of
resistant cells, CR, and CR=P over the range of treatment
schedules specified by the restricted constraint curve from
Figure 6D. As the drug concentration and hence the death rate
of sensitive cancer cells, c1, increase, we move along the constraint
curve from the continuous-dose endpoint towards the high-dose
endpoint. As a particular numerical example, consider an initial
number of sensitive cancer cells of M~109, a mutation rate
conferring resistance of u~5:10{10, and a neutral resistance
mutation (r2~r1,d2~d1). Then the probability of resistance,
shown in Figure 7A, is minimized when c1~3:15. This result is
subsequently used to identify the corresponding optimal treatment
schedule in Figure 6D, which in this case is given by Ton~6:05
days, Toff~21:95 days, and a drug concentration achieving
c1~3:15. When this optimal treatment schedule is used, the
probability of resistance is below 10%. However, if a higher dose is
chosen, the probability of resistance may increase up to 1. This
example illustrates the importance of locating the optimal dosing
regime for the clinical management of patients.
The values proportional to the expected number of resistant
cells, CR, and to the conditional expected number of resistant cells,
CR=P, are displayed in Figures 7B and 7C. Interestingly, in the
event that resistance occurs, the optimal treatment schedule for
Figure 6. Families of toxicity constraints relating the duration of a treatment phase to the death rate of sensitive cancer cells. (A) We
show examples for toxicity constraints which vary the endpoint representing the maximum dose that can be tolerated for a full treatment cycle of
K=Ton days. The treatment cycle is K=28 days, and the endpoint representing the maximum dose that is tolerated for just one day is specified by the
death rate c1=6. Black dots represent different continuous-dose endpoints. (B) We show examples for toxicity constraints which vary the endpoint
representing the maximum dose that can be tolerated for a single day only, Ton=1. Parameters are as above and black points represent the high-
dose endpoints. (C) We show examples for toxicity constraints which vary the degree of the convexity of the curve. Parameters as above. (D) We show
an example for a toxicity constraint (equation (16)) in which the range of c1 is restricted to satisfy the viable treatment option constraint, c,0. The
dotted line shows the full toxicity constraint curve, T1
1, while the solid line shows the portion of the curve in the range in which c,0. Parameters are
r1=1.3, d1=1, and q1=1.3.
doi:10.1371/journal.pcbi.1000557.g006
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which differs from the optimal schedule for minimizing the
probability of developing resistance. For a general cohort of
patients treated with this dosing schedule, the probability of
developing resistance would be close to 1; for the subset of patients
who do develop resistance, however, this dosing schedule would
delay disease progression by the largest amount of time.
Parameter dependence of optimal dosing strategies
Let us now examine the dependence of these optimal dosing
regimens on variations in parameters and toxicity constraints.
Specifically, we investigate the sensitivity of the optimal dosing
strategies to several characteristics of the toxicity curves: the
maximum dose that can be administered for the whole treatment
cycle of K days (the continuous-dose endpoint), the maximum
dose that can be administered for one day only (the high-dose
endpoint), and the degree of concavity of the toxicity curve. The
optimal dosing regimens are identified over a range of parameter
values of r1 and r2.
First, we consider the family of curves Ti
1 for i~1,2,3 (equations
(15) and (14) as shown in Figure 6A). The optimal dosing strategy
minimizing the probability of resistance and/or the conditional
number of resistant cells is displayed in Figure 8. In column (A), we
show the value of c1 that corresponds to the dosing schedule which
minimizes the probability of resistance for a given r1 and r2. The
corresponding minimal probability of resistance is shown in
column (C). Column (B) displays the value of c1 that specifies the
dosing schedule minimizing the conditional expected number of
resistant cells, i.e. maximizing the amount of time until disease
progression in patients who develop resistance. The rows show the
results for constraints T1
1,T2
1, and T3
1, respectively. Note that the
optimal dosing schedules in the first and second column are not
identical, reflecting the fact that the recommended dosing
regimens for these two clinical goals are different. In addition,
we observe that as the continuous-dose endpoint is varied, the
minimal probability of resistance changes (in column (C)) while the
optimal dosing schedules remain relatively unchanged. In
particular, the minimal probability of resistance decreases as the
continuous-dose endpoint shifts to the right.
Next we consider the family of curves Ti
2, for i~1,2,3
(equations (15) and (16), shown in Figure 6B). We plot the results
in Figure 9, where the columns show the optimal treatment
schedules and the probability of resistance for constraints T1
2,T2
2,
and T3
2, respectively. For both clinical goals of minimizing the
probability of resistance and maximizing the time until detection
of resistance, we observe that as the maximum dose tolerated for
one day (the high-dose endpoint) is increased, the optimal dosing
schedule shifts slightly to a more high-dose pulsed regimen in some
regions of the parameter space (particularly when r1 is small).
However, the minimal probability of resistance changes only
slightly as this endpoint is increased.
Lastly, we consider the family of curves Ti
3, for i~1,2,3
(equation (17), shown in Figure 6C). We plot the results in
Figure 10. The columns again show the optimal schedules and the
probability of resistance for constraints T1
3,T2
3, and T3
3. The results
for the first two constraints, T1
3 and T2
3, differ markedly from those
of T3
3. In particular, for functions with a lower degree of convexity,
a high-dose pulsed treatment is optimal for both clinical goals. For
these cases a minimal probability of resistance near zero can be
achieved. However, for T3
3 the optimal dosing schedule shifts more
towards the continuous end of the dosing spectrum, and in certain
parameter ranges the minimal probability of resistance reaches
higher values.
Figure 7. The identification of optimum dosing strategies. (A)
We show the probability of resistance, P, over the range of treatment
schedules specified by the restricted (solid) constraint curve from
Figure 6(d). The probability of resistance is minimized when c1=3.15.
We can then use the toxicity constraint curve to identify all other
specifications of the dosing schedule, such as Ton, Toff, the concentration
etc. Parameters are r1=1.3, d1=1,q1=1.3, r2=1.3, d2=1,M=10
9, and
u=5?10
210. (B) We show the time-independent term of the equation
describing the number of resistant cells, CR, over the same constraint
curve as above. This term is minimized when c1=3.4, which does not
coincide with the optimum dosing strategy identified in (A). Therefore
the strategy minimizing the probability of resistance may not coincide
with the strategy maximizing the time until detection of resistant cells.
(C) We show the value proportional to the conditional number of
resistant cells, CR/P, over the same constraint curve. Parameters are as
above.
doi:10.1371/journal.pcbi.1000557.g007
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So far we have only considered treatment strategies during which
the total number of sensitive cancer cells declines on average, i.e.
when cv0 holds. However, for some therapies and cancer types
it is impossible to reduce the number of sensitive cancer cells. Then
the goal of therapy becomes to slow or even halt the rate of tumor
growth. For these cases, the probability of resistance is always one.
However, we can still identify treatment schedules that maximally
delay progression of disease by controlling the number of resistant
cells. The approximations for the expected number of resistant cells
derived above remain valid, except when c~0. In this case, we
revisitthecalculationofB(t) andestimatethetotalnumberofbirths
during on- and off-treatment phases as
X Wt
i~1
Ci~Mf(Ton,q1,c1)
X Wt
i~1
1~Mf(Ton,q1,c1)Wt ð19Þ
X Wt
i~1
Di~Mf(Toff,r1,d1)eaonTon
X Wt
i~1
1~Mf(Ton,q1,c1)eaonTonWt:
Once again making the approximation Wt&t=(TonzToff),w e
obtain
B(t)&
Mt
TonzToff
(f(Ton,q1,c1)zf(Toff,r1,d1)eaonTon):
After taking the convolution of the derivative B’(t) with the
expected growth rate of resistant cells, we obtain the expected
number of resistant cells at time T as
R(T)&
Mut
TonzToff
(f(Ton,q1,c1)zf(Toff,r1,d1)eaonTon)
eT(r2{d2){1
r2{d2
:
Note that for cases when cw0, the formula for the expected
number of resistant cells, equation (10), experiences a singularity in
the denominator when r2{d2~c=½TonzToff , i.e. when the net
growthrate of the resistant cancercells equals the net growth rate of
the sensitive cancer cells. However, the range of therapies
considered should be restricted to those in which the net growth
rate of sensitive cancer cells is less than that of resistant cancer cells;
otherwise, the problem of resistance is secondary to the problem of
controlling the sensitive cell population. In these cases, the
singularity does not occur.
Figure 8. Optimal dosing regimens for the family of toxicity curves in Figure 6(A) under variation of the continuous-dose endpoint.
In column (A), the color at each point represents the value of c1 that corresponds to the dosing schedule which minimizes the probability of
resistance. In column (B), the color at each point represents the value of c1 that corresponds to the dosing schedule which minimizes the conditional
expected number of resistant cells. In column (C), the minimal probability of resistance corresponding to the optimal schedule from column (A) is
plotted. Rows 1,2, and 3 show results for constraints T1
1, T1
2, and T1
3. Parameters are d1=1,q1=1.3, M=10
9, and u=5?10
210.
doi:10.1371/journal.pcbi.1000557.g008
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In this paper, we have constructed a simple mathematical model
using birth and death processes to describe the evolution of
resistance during targeted anti-cancer therapy. We have derived
and validated analytical approximations to this model, which
provide a useful tool for predicting the risk of resistance and the
growth of resistant cell populations under various dosing strategies.
We have used our model and estimates to develop a methodology
for designing optimal drug administration strategies to minimize
the risk of resistance. In cases in which the risk of resistance is high
for any treatment schedule, these strategies are modified to
maximize the time until the progression of disease.
The probability of resistance is shown to be largely dependent
on b, the rate of sensitive cell division, which is the product of the
current sensitive cell population size and its growth rate. Drugs
whose main goal is to increase the death rate of sensitive cells can
decrease the sensitive cell population, thus decreasing b and
reducing the probability of resistance; however, if the initial tumor
size is large, it may take a significant amount of time to deplete the
sensitive cell population. During this delay, there is still a high
probability of generating resistant mutants since the sensitive cell
proliferation rate is unchanged. On the other hand, for drugs that
inhibit sensitive cell proliferation and effectively reduce the growth
rate of sensitive cells, the quantity b is immediately reduced to zero
regardless of the initial size of the tumor. This implies that drugs
that inhibit cancer cell proliferation could be promising for the
prevention of resistance in the absence of pre-existing resistant cell
clones. Combination therapies in which an inhibitor of sensitive
cell proliferation is dosed continuously while short, high pulses of a
drug that increases the death rate of resistant cells are
administered may also be of interest, as are any combination
strategies which separately target the sensitive and resistant
populations.
We have also extended the theory to incorporate pre-existing
resistant cells at the start of therapy. The effect of pre-existing
resistant clones on the optimal dosing strategy is highly dependent
upon system parameters including the growth and death rates of
sensitive and resistant cells, the initial tumor size, and initial
number of resistant cells. Consider the probability of resistance in
this scenario, given by equation (13). We note that the term Pe
r,
denoting the probability of extinction of the pre-existing clone,
consists of the Ms-th power of a quantity usually less than one
(d2=r2). Thus even a small population of pre-existing resistant cells
can cause the total probability of resistance to be effectively equal
to one. For example, if the growth rate of resistant cells is twice
Figure 9. Optimal dosing regimens for the family of toxicity curves in Figure 6(B) under variation of the high-dose endpoint. In
column (A), the color at each point represents the value of c1 that corresponds to the dosing schedule which minimizes the probability of resistance.
In column (B), the color at each point represents the value of c1 that corresponds to the dosing schedule which minimizes the conditional expected
number of resistant cells. In column (C), the minimal probability of resistance corresponding to the optimal schedule from column (A) is plotted. Rows
1,2, and 3 show results for constraints T1
1, T1
2, and T1
3. Parameters are d1=1,q1=1.3, M=10
9, and u=5?10
210.
doi:10.1371/journal.pcbi.1000557.g009
Evolution of Resistance to Targeted Therapies
PLoS Computational Biology | www.ploscompbiol.org 15 November 2009 | Volume 5 | Issue 11 | e1000557their death rate, then the probability of extinction for an initial
population consisting of only 30 resistant cells evaluates to
0:530&10{10. Then the total probability of resistance, given by
equation (13), is approximately one. Therefore, the presence of
even a small number of resistant cells at the start of therapy can
effectively prevent a cure. In these cases, we may instead attempt
to delay disease progression by controlling the number of resistant
cells. Equation (14) describes the current size of the resistant
population as the sum of the average de novo and pre-existing
resistant clone sizes. Observe that both terms in this expression
grow at the same exponential rate; the term for pre-existing
resistance starts at time zero with the value Ms, while the term for
de novo resistance starts with value zero at time zero. This fact has
implications for treatment schedules in the case of pre-existing
resistance: as long as an eventual decline of sensitive cancer cells is
achieved, high-dose strategies which slow the effective net growth
rate of resistant cells may be more effective than low-dose
strategies aimed at maximal continuous inhibition of sensitive cells.
By testing several families of toxicity constraints, we have
observed that the optimal dosing strategies are strongly affected by
the degree of convexity of the toxicity curve, thus delineating a
clear priority in experimental efforts to determine the parameters
of this constraint. In our experience of studying published results of
Phase I clinical trials of molecularly targeted anti-cancer therapies,
patient toxicity reports are usually not detailed enough to
accurately determine toxicity curves. In light of our observations,
we would like to stress the importance of publishing detailed
quantitative data on toxicity in clinical trials, so that statistical
analyses can be performed to inform these constraint curves. It is
also important to estimate the growth and death rates of sensitive
and resistant cancer cells during administration of diverse drug
concentrations. These curves can be estimated by studying the
growth and death kinetics of cancer cells, either in vivo or in vitro.
For example, in vitro net growth rates can be determined by
subjecting sensitive and resistant cell populations to drug at
varying concentrations and counting viable cells at multiple time
points. Then, through fluorescence-activated cell sorting tech-
niques, the amount of cell death at multiple time points can be
observed, providing the cell death rate at each drug concentration.
If the parameters of the model are also estimated for treatment
with conventional cytotoxic chemotherapeutics, then our model
can be applied to these treatment choices as well. This
methodology, together with key parameters derived experimen-
tally, can aid in the design of optimum administration strategies of
treatment options for all cancer types that evolve resistance via a
single (epi)genetic alteration.
Figure 10. Optimal dosing regimens for the family of toxicity curves in Figure 6(C) under variation of the convexity of the toxicity
constraint. In column (A), the color at each point represents the value of c1 that corresponds to the dosing schedule which minimizes the
probability of resistance. In column (B), the color at each point represents the value of c1 that corresponds to the dosing schedule which minimizes
the conditional expected number of resistant cells. In column (C), the minimal probability of resistance corresponding to the optimal schedule from
column (A) is plotted. Rows 1,2, and 3 show results for constraints T1
1, T1
2, and T1
3. Parameters are d1=1,q1=1.3, M=10
9, and u=5?10
210.
doi:10.1371/journal.pcbi.1000557.g010
Evolution of Resistance to Targeted Therapies
PLoS Computational Biology | www.ploscompbiol.org 16 November 2009 | Volume 5 | Issue 11 | e1000557Acknowledgments
The authors would like to thank Juliann Chmielecki, Ross Levine, Mark
Lipson, William Pao, and the Michor Lab for discussion and comments.
Author Contributions
Conceived and designed the experiments: JF FM. Performed the
experiments: JF. Analyzed the data: JF FM. Contributed reagents/
materials/analysis tools: JF. Wrote the paper: JF FM.
References
1. Ross K (2004) Targeted therapies for cancer 2004. Am J Clin Path 122:
598–609.
2. Sawyers C (2004) Targeted cancer therapy. Nature 432: 294–297.
3. Gorre M, Mohammed M, Ellwood K, Hsu N, Paquette R, et al. (2001) Clinical
resistance to sti-571 cancer therapy caused by bcr-abl gene mutation or
amplification. Science 293: 876–880.
4. Burgess M, Sawyers C (2006) Drug-resistant phosphatidylinositol 3-kinase:
Guidance for the preemptive strike. Scientific World Journal 11: 918–930.
5. Pao W, Miller V, Politi K, GJ GR, Somwar R, et al. (2005) Acquired resistance
of lung adenocarcinomas to gefitinib or erlotinib is associated with a second
mutation in the egfr kinase domain. PLoS Medicine 2.
6. Bentires-Alj M, Barbu V, Fillet M, et al. (2003) Nf-kb transcription factor
induces drug resistance through mdr1 expression in cancer cells. Oncogene 22:
90–97.
7. Chiang C, Sawyers C, Mcbride W (1998) Oncogene expression and cellular
radiation resistance: A modulatory role for c-myc. Mol Diagn 3: 21–27.
8. Clynes M (1998) Multiple drug resistance in cancer 2: molecular, cellular and
clinical aspects Kluwer Academic.
9. Dowsett M (2001) Overexpression of her-2 as a resistance mechanism to
hormonal therapy for breast cancer. Endocr Relat Cancer 8: 191–195.
10. Gupta A, Bakanauskas V, Cerniglia G, et al. (2001) The ras radiation resistance
pathway. Cancer Res 61: 4278–4282.
11. Townsend D, Tew K (2003) The role of glutathione-s-transferase in anticancer
drug resistance. Oncogene 22: 77369–7375.
12. Hryniuk W (2001) Dosage parameters in chemotherapy of breast cancer. Breast
Disease 14: 21–30.
13. Lake D, Hudis C (2004) High-dose chemotherapy in breast cancer. Drugs 64:
1851–1860.
14. Hahnfeldt P, Folkman J, Hlatky L (2003) Minimizing long-term tumor burden:
The logic for metronomic chemotherapeutic dosing and its antiangiogenic basis.
J Theor Biol 220: 545–554.
15. Norton L, Simon R (1977) Tumor size, sensitivity to therapy, and design of
treatment schedules. Cancer Treat Rep 61: 1307–1317.
16. Norton L, Simon R (1986) The norton-simon hypothesis revisited. Cancer Treat
Rep 70: 163–169.
17. Citron M, et al. (2003) Randomized trial of dose-dense versus conventionally
scheduled and sequential versus concurrent combination chemotherapy as
postoperative adjuvant treatment of node-positive primary breast cancer: first
report of intergroup trial c9741/cancer and leukemia group b trial 9741. J Clin
Oncol 21: 1431–1439.
18. Dibrov B, Zhabotinsky A, Neyfakh Y, Orlova M, Churikova L (1983) Optimal
scheduling for cell synchronization by cycle-phase-specific blockers. Math Biosci
66: 167–185.
19. Agur Z (1986) The effect of drug schedule on responsiveness to chemotherapy.
Ann Acad New York Sci 504: 274–277.
20. Panetta J (1996) A mathematical model of periodically pulsed chemotherapy:
Tumor recurrence and metastasis in a competitive environment. Bull Math Biol
58: 425–447.
21. Costa M, Boldrini J, Bassanezi R (1995) Drug kinetics and drug resistance in
optimal chemotherapy. Math Biosci 125: 191–209.
22. Gardner S, Fernandes M (2003) Newt o o l sf o rc a n c e rc h e m o t h e r a p y :
computational assistance for tailoring treatments. Mol Cancer Therapeutics 2:
1079–D1084.
23. Swan G (1990) Role of optimal control in chemotherapy. Math Biosci 101:
237–284.
24. Martin R, Teo K (1994) Optimal control of drug administration in cancer
chemotherapy World Scientific Publishin.
25. Coldman A, Goldie J (1986) A stochastic model for the origin and treatment of
tumors containing drug-resistant cells. Bull Math Biol 48: 279–292.
26. Coldman A, Murray J (2000) Optimal control for a stochastic model of cancer
chemotherapy. Math Biosciences 168: 187–200.
27. Day R (1986) Treatment sequencing, asymmetry, and uncertainty: Protocol
strategies for combination chemotherapy. Cancer Research 46: 3876–3885.
28. Iwasa Y, Michor F, Nowak M (2003) Evolutionary dynamics of escape from
biomedical intervention. Proc Roy Soc Lond B 270: 2572–2578.
29. Komarova N, Wodarz D (2005) Drug resistance in cancer: Principles of
emergence and prevention. PNAS 102: 9714–9719.
30. Komarova N (2006) Stochastic modeling of drug resistance in cancer. J Theor
Biol 239: 351–366.
31. Iwasa Y, Nowak M, Michor F (2006) Evolution of resistance during clonal
expansion. Genetics 172: 2557–2566.
32. Haeno H, Y YI, Michor F (2007) The evolution of two mutations during clonal
expansion. Genetics 177: 2209–2221.
33. Athreya K, Ney P (2004) Branching processes Dover Press.
34. Hidalgo M, Siu L, Nemunaitis J, et al. (2001) Phase I and pharmacologic study
of osi-774, and epidermal growth factor receptor tyrosine kinase inhibitor, in
patients with advanced solid malignancies. Journal of Clinical Oncology 19:
3267–3279.
35. Soulieres D, Senzer N, Vokes E, et al. (2004) Multicenter phase II study of
erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in
patients with recurrent or metastatic squamous cell cancer of the head and neck.
Journal of Clinical Oncology 11: 77–85.
36. Milton D, Azzoli C, Heelan R, et al. (2006) A phase I/II study of weekly high-
dose erlotinib in previously treated patients with nonsmall cell lung cancer.
Cancer 107: 1034–1041.
Evolution of Resistance to Targeted Therapies
PLoS Computational Biology | www.ploscompbiol.org 17 November 2009 | Volume 5 | Issue 11 | e1000557